Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders

Yosiro Sawae, Yoshiyuki Niho, Takashi Okamura, Hisashi Gondo, Mitsuo Kozuru, Naokuni Uike, Koichiro Muta, Tatsuro Goto, Yoko Suehiro, Midori Kumakawa, Junji Nlshimura, Yuji Yufu, Hldeki Ishikura, Sayuri Yamashita, Syusuke Hisano, Em Morioka, Hiroaki Nakajima, Tsunefumi Shibuya, Kazuo Yamasaki, Naoki HaradaRyokichi Asayama, Shin Hayashi, Kouichi Akashi, Eiichi Suematsu, Seiji Motomura, Yusei Yamamoto, Toru Takada, Kimiaki Ikeda, Fumihiro Taguchi, Yujiroh Yamano, Masako Taniouchi, Eijo Matsuishi, Yoshinobu Asano, Chiyuki Kawasaki

Research output: Contribution to journalArticle

Abstract

One hundred and nine patients with infections concurrent with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS) either alone (IPM/CS monotherapy) or in combination with other antimicrobial drugs (IPM/CS combination therapy). The following results were obtained.

Original languageEnglish
Pages (from-to)10-13
Number of pages4
JournalJapanese Journal of Antibiotics
Volume49
Issue number12
Publication statusPublished - 1996

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders'. Together they form a unique fingerprint.

Cite this